IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Previously Presented): A medicinal product for antitumor immunotherapy in an HLA-B35 patient comprising at least one immunogenic peptide representing a T epitope presented by MHC I, selected from the group consisting of:

a) a peptide comprising the sequence $EX_1AGIGILX_2$ (SEQ ID NO : 1) in which X_1 represents A or P, and X_2 represents T or Y, capable of inducing a cytotoxic response directed against the Melan-A antigen;

b) a peptide comprising the sequence EVDPIGHVY (SEQ ID NO : 2), capable of inducing a cytotoxic T response directed against the MAGE-A6 antigen;

c) a peptide comprising the sequence VPLDCVLYR (SEQ ID NO : 3), capable of inducing a cytotoxic response directed against the gp100 antigen;

d) a peptide comprising the sequence TPRLPSSADVEF (SEQ ID NO : 4), capable of inducing a cytotoxic response directed against the tyrosinase antigen; and

e) a peptide comprising the sequence MPFATPMEA (SEQ ID NO : 5), capable of inducing a cytotoxic response directed against the NY-ESO-1 antigen.

Claim 2 (Previously Presented): The medicinal product of claim 1, wherein said peptide is selected from the group consisting of:

a) a peptide of sequence selected from the group consisting of TAEEAAGIGILTV (SEQ ID NO : 6), EAAGIGILTVIL (SEQ ID NO : 7), EAAGIGILTV (SEQ ID NO : 8), EAAGIGILTY (SEQ ID NO : 9), EAAGIGILY (SEQ ID NO:10),EPAGIGILTY (SEQ ID NO:11), and EPAGIGILTV (SEQ ID NO : 12);

b) a peptide of sequence EVDPIGHVY (SEQ ID NO : 2);

c) a peptide of sequence selected from the group consisting of VPLDCVLYR (SEQ ID NO : 3) and VPLDCVLYRY (SEQ ID NO : 13);

d) a peptide of sequence selected from the group consisting of TPRLPSSADVEFCL (SEQ ID NO : 15) and TPRLPSSADVEF (SEQ ID NO : 4); and

e) a peptide of sequence selected from the group consisting of LAMPFATPMEAEL (SEQ ID NO : 16), LAMPFATPMEAE (SEQ ID NO : 17), MPFATPMEAEL (SEQ ID NO : 18), MPFATPMEAE (SEQ ID NO : 19) and MPFATPMEA (SEQ ID NO : 5).

Claim 3 (Previously Presented): An immunogenic peptide representing a T epitope presented by MHC I, selected from the group consisting of:

- a peptide of sequence selected from the group consisting of EAAGIGILTY (SEQ ID NO : 9), EAAGIGILY (SEQ ID NO : 10), EPAGIGILTY (SEQ ID NO : 11), and EPAGIGILTV (SEQ ID NO : 12);

- a peptide of sequence selected from the group consisting of VPLDCVLYR (SEQ ID NO : 3), VPLDCVLYRY (SEQ ID NO : 13) and PVPLDCVLYRY (SEQ ID NO : 14); and

- a peptide of sequence selected from the group consisting of TPRLPSSADVERFCL (SEQ ID NO : 15) and TPRLPSSADVEF (SEQ ID NO : 4).

Claim 4 (Withdrawn): A multiepitope composition comprising at least two peptides of two different categories among the categories a), b), c), d) and e) as defined in claim 1.

Claim 5 (Withdrawn): A multiepitope composition comprising at least one peptide from each of categories a), b), c), d) and e) as defined in claim 1.

Claim 6 (Withdrawn): The multiepitope composition as claimed in claim 4, consisting of a chimeric polypeptide comprising one or more copies of each of said peptides.

Claim 7 (Withdrawn): A polynucleotide encoding a chimeric polypeptide as claimed in claim 6.

Claim 8 (Withdrawn): An antigen-presenting cell expressing an MHC I HLA-B35 allele, wherein said cell expresses a peptide as defined in claim 1.

Claim 9 (Withdrawn): An antigen-presenting cell expressing an MHC I HLA-B35 allele, wherein said cell is transfected with a polynucleotide as claimed in claim 7.

Claim 10 (Withdrawn): A method for *in vitro* detection of CTLs directed against one or more of antigens selected from the group consisting of Melan-A, MAGE-A6, gp100, tyrosinase and NY-ESO-1, comprising

obtaining a biological sample from an HLA-B35 individual;

contacting said biological sample with at least one peptide defined in claim 1; and

detecting the presence or absence of a CTL directed against one or more of the antigens selected from the group consisting of Melan-A, MAGE-A6, gp100, tyrosinase and NY-ESO-1.

Claim 11 (Withdrawn): The multiepitope composition as claimed in claim 5, consisting of a chimeric polypeptide comprising one or more copies of each of said peptides.

Claim 12 (Withdrawn): A polynucleotide encoding a chimeric polypeptide as claimed in claim 11.

Claim 13 (Withdrawn): An antigen-presenting cell expressing an MHC I HLA-B35 allele, wherein said cell is transfected with a polynucleotide as claimed in claim 12.

Claim 14 (Withdrawn): A multiepitope composition comprising at least two peptides of two different categories among the categories a), b), c), d) and e) as defined in claim 2.

Claim 15 (Withdrawn): The multiepitope composition as claimed in claim 14, consisting of a chimeric polypeptide comprising one or more copies of each of said peptides.

Claim 16 (Withdrawn): A polynucleotide encoding a chimeric polypeptide as claimed in claim 15.

Claim 17 (Withdrawn): An antigen-presenting cell expressing an MHC I HLA-B35 allele, wherein said cell is transfected with a polynucleotide as claimed in claim 16.

Claim 18 (Withdrawn): A multiepitope composition comprising at least one peptide from each of categories a), b), c), d) and e) as defined in claim 2.

Claim 19 (Withdrawn): The multiepitope composition as claimed in claim 18, consisting of a chimeric polypeptide comprising one or more copies of each of said peptides.

Claim 20 (Withdrawn): A polynucleotide encoding a chimeric polypeptide as claimed in claim 19.

Claim 21 (Withdrawn): An antigen-presenting cell expressing an MHC I HLA-B35 allele, wherein said cell is transfected with a polynucleotide as claimed in claim 20.

Claim 22 (Withdrawn): An antigen-presenting cell expressing an MHC I HLA-B35 allele, wherein said cell expresses a peptide as defined in claim 2.

Claim 23 (Withdrawn): A method for *in vitro* detection of CTLs directed against one or more of antigens selected from the group consisting of Melan-A, MAGE-A6, gp100, tyrosinase and NY-ESO-1, comprising

obtaining a biological sample from an HLA-B35 individual;

contacting said biological sample with at least one peptide defined in claim 2; and

detecting the presence or absence of a CTL directed against one or more of the antigens selected from the group consisting of Melan-A, MAGE-A6, gp100, tyrosinase and NY-ESO-1.

Claim 24 (Withdrawn): A method for *in vitro* detection of CTLs directed against one or more of antigens selected from the group consisting of Melan-A, MAGE-A6, gp100, tyrosinase and NY-ESO-1, comprising

obtaining a biological sample from an HLA-B35 individual;

contacting said biological sample with at least one peptide defined in claim 3; and

detecting the presence or absence of a CTL directed against one or more of the antigens selected from the group consisting of Melan-A, MAGE-A6, gp100, tyrosinase and NY-ESO-1.

Claim 25 (New): The medicinal product for antitumor immunotherapy in an HLA-B35 patient according to Claim 1 further comprising at least another immunogenic peptide representing a T epitope presented by MHC I, selected from the group consisting of:

a) a peptide comprising the sequence $EX_1AGIGILX_2$ (SEQ ID NO : 1) in which X_1 represents A or P, and X_2 represents T or Y, capable of inducing a cytotoxic response directed against the Melan-A antigen;

b) a peptide comprising the sequence EVDPIGHVY (SEQ ID NO : 2), capable of inducing a cytotoxic T response directed against the MAGE-A6 antigen;

c) a peptide comprising the sequence VPLDCVLYR (SEQ ID NO : 3), capable of inducing a cytotoxic response directed against the gp100 antigen;

d) a peptide comprising the sequence TPRLPSSADVEF (SEQ ID NO : 4), capable of inducing a cytotoxic response directed against the tyrosinase antigen; and

e) a peptide comprising the sequence MPFATPMEA (SEQ ID NO : 5), capable of inducing a cytotoxic response directed against the NY-ESO-1 antigen;

wherein the immunogenic peptides representing a T epitope presented by MHC I belong to different categories a) to e).

Claim 26 (New): The medicinal product for antitumor immunotherapy in an HLA-B35 patient according to claim 1 comprising at least immunogenic peptide representing a T epitope presented by MHC I, selected from each member of the group consisting of:

a) a peptide comprising the sequence $EX_1AGIGILX_2$ (SEQ ID NO : 1) in which X_1 represents A or P, and X_2 represents T or Y, capable of inducing a cytotoxic response directed against the Melan-A antigen;

b) a peptide comprising the sequence EVDPIGHVY (SEQ ID NO : 2), capable of inducing a cytotoxic T response directed against the MAGE-A6 antigen;

c) a peptide comprising the sequence VPLDCVLYR (SEQ ID NO : 3), capable of inducing a cytotoxic response directed against the gp100 antigen;

d) a peptide comprising the sequence TPRLPSSADVEF (SEQ ID NO : 4), capable of inducing a cytotoxic response directed against the tyrosinase antigen; and

e) a peptide comprising the sequence MPFATPMEA (SEQ ID NO : 5

Claim 27 (New): The medicinal product for antitumor immunotherapy in an HLA-B35 patient according to Claim 1 comprising at least one chimeric polypeptide of an immunogenic peptide representing a T epitope presented by MHC I, selected from the group consisting of:

a) a peptide comprising the sequence $EX_1AGIGILX_2$ (SEQ ID NO : 1) in which X_1 represents A or P, and X_2 represents T or Y, capable of inducing a cytotoxic response directed against the Melan-A antigen;

b) a peptide comprising the sequence EVDPIGHVY (SEQ ID NO : 2), capable of inducing a cytotoxic T response directed against the MAGE-A6 antigen;

c) a peptide comprising the sequence VPLDCVLYR (SEQ ID NO : 3), capable of inducing a cytotoxic response directed against the gp100 antigen;

d) a peptide comprising the sequence TPRLPSSADVEF (SEQ ID NO : 4), capable of inducing a cytotoxic response directed against the tyrosinase antigen; and

e) a peptide comprising the sequence MPFATPMEA (SEQ ID NO : 5), capable of inducing a cytotoxic response directed against the NY-ESO-1 antigen.